© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Joshua M. Bauml, MD, provides insight on the treatment of ALK fusion+ non-small cell lung cancer with tyrosine kinase inhibitors.
April 15th 2021
Joshua M. Bauml, MD, presents the case of a 57-year-old man with ALK fusion+ non-small-cell lung cancer (NSCLC) and discusses recommended molecular tests to identify patients with molecular driver alterations.
Approaching TKI (tyrosine kinase inhibitor)-based therapy for the first-line management of ALK+ mNSCLC.
A review of the open-label, phase 3 ALTA-1L trial comparing the use of brigatinib to crizotinib in ALK+ metastatic non-small-cell lung cancer.
Managing patients with who progress on a TKI, the role of re-biopsy at progression of disease, and the future treatment landscape for ALK+ mNSCLC.